1. Home
  2. CPOP vs RNTX Comparison

CPOP vs RNTX Comparison

Compare CPOP & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pop Culture Group Co. Ltd

CPOP

Pop Culture Group Co. Ltd

HOLD

Current Price

$0.31

Market Cap

36.4M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.00

Market Cap

47.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CPOP
RNTX
Founded
2007
2001
Country
China
United States
Employees
N/A
10
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.4M
47.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
CPOP
RNTX
Price
$0.31
$1.00
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
258.0K
196.6K
Earning Date
11-17-2025
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.02
52 Week High
$2.60
$2.22

Technical Indicators

Market Signals
Indicator
CPOP
RNTX
Relative Strength Index (RSI) 49.20 32.18
Support Level $0.30 N/A
Resistance Level $0.36 $1.45
Average True Range (ATR) 0.04 0.19
MACD -0.00 -0.08
Stochastic Oscillator 35.58 3.18

Price Performance

Historical Comparison
CPOP
RNTX

About CPOP Pop Culture Group Co. Ltd

Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: